A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Summary

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Systemic Lupus Erythematosus

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 74 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Boehringer Ingelheim

Last updated on ClinicalTrials.gov

October 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites